공고 • 12h
Tristel plc Announces Commercial Launch Of 3T Pro Premium Tier Within 3T Digital Compliance Platform Tristel plc had announced the commercial launch of 3T Pro, a premium tier within its 3T digital compliance platform. This launch marks the first time the Company has introduced a paid model for 3T, representing a significant step in Tristel's strategy to develop recurring digital revenue streams alongside its core product portfolio. Since its introduction, 3T has been offered as a free-to-use tool to work alongside Tristel disinfection products, supporting healthcare providers with staff training management and compliance tracking. 3T Pro is built and maintained by the Company's well established in-house software team, whose ownership of the platform allows priorities to be reshaped quickly in response to customer feedback and the growing compliance, audit and operational demands of healthcare providers. This has enabled the introduction of enhanced asset tracking and lifecycle management, sophisticated dashboards, structured audit reporting, and a scalable data architecture to support future integrations. The launch formalises a three-tier product structure: a free entry-level tier covering core training and compliance functionality; a mid-tier combining training management with device traceability; and 3T Pro, a premium tier delivering advanced customisation, workflows, reporting and audit readiness capabilities. To protect its installed base, Tristel will offer transitional licensing arrangements to existing users of traceability features, while customers upgrading to 3T Pro will access the full suite of advanced capabilities under standard commercial terms. The entry-level tier remains free to support broad accessibility and adoption across the healthcare sector. 공고 • Jul 07
Tristel PLC Showcases And Launches New Products At APIC26 Annual Conference Tristel PLC participated at APIC 2026, the largest annual infection prevention and control conference in the United States, which took place in Nashville, Tennessee from 15-17 June 2026. The Company, together with its U.S. commercial partner Parker Laboratories, co-sponsored a fully-attended session in the APIC Exhibitor Theatre, in which three infection prevention and clinical leaders shared real-world experience of implanting Tristel ULT, the Company's FDA-cleared chlorine dioxide foam for the high-level disinfection of ultrasound probes. Speakers described measurable operational benefits including faster room turnaround, significant reductions in annual maintenance costs, successful accreditation survey outcomes, and the role of digital traceability tools in strengthening documentation and audit readiness. The session built on two scientific posters on Tristel ULT presented earlier in 2026 at the annual meetings of the Society for Healthcare Epidemiology of America and the American Institute in Ultrasound Medicine, underlining the growing body of clinical evidence and advocacy supporting Tristel's technology among U.S. practitioners. Engagement with existing U.S. customers was a further highlight of the conference, with continued strong interest in Tristel's technology from current users and growing awareness of additional applications for the Company's chlorine dioxide chemistry across departments beyond those in which customers are already established. In addition, Tristel showcased Tristel ORL, a high-level disinfectant foam for ear, nose and throat devices, to the U.S. clinicians and infection prevention professionals at APIC for the first time. Based on data supporting its recently granted Health Canada registration, Tristel ORL is intended to provide high-level disinfection with a two-minute contact time and is designed for use at the point-of-care. The Company is progressing towards FDA submission, with APIC providing valuable platform to gather direct feedback from clinicians in anticipation of the regulatory review. Tristel also formally launched Tristel 3T Pro, the first paid tier of its 3T digital compliance platform. As the first paid tier, 3T Pro introduces advanced customisation, reporting and audit-readiness features, and represents a meaningful step towards building recurring digital revenue alongside the core product portfolio. 공고 • Mar 03
Tristel plc Recommends Interim Dividend for the Year Ended 30 June 2026, Payable on 9 April 2026 The Board of Tristel plc recommended an interim dividend of 5.68 pence (2024: 5.68 pence) for the year ended 30 June 2026 to be paid on 9 April 2026. The associated ex-dividend date will be 19 March 2026 with a record date of 20 March 2026. 공고 • Feb 06
Tristel plc to Report First Half, 2026 Results on Mar 02, 2026 Tristel plc announced that they will report first half, 2026 results on Mar 02, 2026 공고 • Jan 22
Tristel plc Announces Resignation of Matt Sassone as Chief Executive Officer Tristel plc announced that Matt Sassone, Chief Executive Officer, has confirmed to the Board his decision to resign to take up a worldwide President role with a large US multinational, leading a significant global business. Matt will actively continue in post until the end of the financial year and has fully committed to continue leading the business through this period. The Board has already commenced the process to appoint a new CEO and is confident that there is sufficient management depth in the business to ensure that trading will not be impacted during the transition. 공고 • Nov 24
Tristel plc Updates US Guidelines for High Level Disinfection Tristel plc expanded guidelines on the handling and reprocessing of ultrasound probes in healthcare environments. For the first time, the AIUM guidelines include chlorine dioxide as an accepted option for high-level disinfection ("HLD"). Chlorine dioxide for ultrasound probe disinfection is branded as Tristel's HLD foam product, Tristel ULT™, in the United States ("US"). Tristel ULT™ is manufactured and distributed by Parker Laboratories under an exclusive partnership agreement with Tristel, and is the only FDA-cleared chlorine dioxide foam disinfectant for ultrasound probes available in the US market. 
